Royal Bank of Canada’s NRX Pharmaceuticals NRXP Stock Holding History

Royal Bank of Canada’s Portfolio NRXP Stock Details NRXP Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$5K	Buy	2,509 +509	+25%	+$1.03K	﹤0.01%	6433
2025 Q4	$5K	Buy	+2,000	New	+$5.37K	﹤0.01%	6721
2024 Q3	–	Sell	-4,013	Closed	-$10K	–	7235
2024 Q2	$10K	Buy	4,013 +4,000	+30,769%	+$14.2K	﹤0.01%	6343
2024 Q1	$0	Sell	13 -15,008	-100%	-$69.2K	﹤0.01%	7403
2023 Q4	$69K	Sell	15,021 -2,021	-12%	-$6.67K	﹤0.01%	5833
2023 Q3	$44K	Sell	17,042 -81	-0.5%	-$269	﹤0.01%	5849
2023 Q2	$83K	Buy	17,123 +17,110	+131,615%	+$103K	﹤0.01%	5469
2023 Q1	$0	Hold	13	–	–	﹤0.01%	7342
2022 Q4	$0	Sell	13 -19	-59%	-$191	﹤0.01%	7555
2022 Q3	$0	Sell	32 -20	-38%	-$135	﹤0.01%	7710
2022 Q2	$0	Buy	+52	New	+$683	﹤0.01%	7597
2021 Q3	–	Sell	-800	Closed	-$93K	–	7790
2021 Q2	$93K	Buy	+800	New	+$211K	﹤0.01%	5653

Other funds holding NRXP

BGI

B Group Inc Dallas, Texas $135M AUM 80% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

AdvisorShares Investments Bethesda, Maryland $549M AUM 32.58% 1-Year Est. Return

Commonwealth Equity Services Waltham, Massachusetts $79.5B AUM 27.1% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

VFT

Vanguard Fiduciary Trust Malvern, Pennsylvania $396B AUM

BFG

Bleakley Financial Group Fairfield, New Jersey $6.39B AUM 26.33% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

XTX Topco George Town, Cayman Islands $5.75B AUM 30.56% 1-Year Est. Return

Royal Bank of Canada's NRXP Position: Q1 2026 in Review

Royal Bank of Canada increased its NRX Pharmaceuticals (NRXP) stake by 25% in Q1 2026, buying an estimated $1.03K and bringing the position to 2,509 shares worth $5K. The position accounts for ﹤0.01% of the portfolio, ranked #6433.

Royal Bank of Canada first reported a position in NRXP in Q2 2021 and has held it in 12 quarters since. The position peaked at $93K in Q2 2021. 33 funds tracked by Wall St. Rank hold NRXP as of Q1 2026.

Royal Bank of Canada held 2,509 shares of NRX Pharmaceuticals worth $5K as of Q1 2026.
Royal Bank of Canada bought 509 NRX Pharmaceuticals shares in Q1 2026, an estimated $1.03K.
NRX Pharmaceuticals made up ﹤0.01% of Royal Bank of Canada's portfolio in Q1 2026, its #6433 holding.
Royal Bank of Canada first reported a position in NRX Pharmaceuticals in Q2 2021 and has held it in 12 quarters since.
Royal Bank of Canada's NRX Pharmaceuticals position peaked at $93K in Q2 2021.
33 funds tracked by Wall St. Rank held NRX Pharmaceuticals as of Q1 2026.

Based on Royal Bank of Canada's 13F filing for Q1 2026, filed 15 May 2026.